Short Interest in CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Expands By 82.3%

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 394,744 shares, an increase of 82.3% from the June 15th total of 216,478 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 1,137,720 shares, the short-interest ratio is presently 0.3 days.

Analysts Set New Price Targets

Several analysts have recently commented on CSLLY shares. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Zacks Research downgraded CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Citigroup cut CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

CSL Trading Up 1.5%

Shares of CSL stock opened at $21.76 on Friday. CSL has a fifty-two week low of $16.01 and a fifty-two week high of $44.85. The business’s fifty day moving average is $18.99 and its two-hundred day moving average is $33.12. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.